Current Report Filing (8-k)
12 January 2023 - 10:22PM
Edgar (US Regulatory)
0001711933
false
0001711933
2023-01-08
2023-01-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 8, 2023
Akoya Biosciences, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
001-40344 |
47-5586242 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
100 Campus Drive, 6th Floor
Marlborough, MA
(Address of principal executive offices) |
01752
(Zip Code) |
(855) 896-8401
(Registrant’s telephone number, including
area code)
Check the appropriate box below
if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
Common stock, par value $0.00001 per share |
|
AKYA |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.02 | Results of Operations and Financial Condition. |
On January 8, 2023, Akoya Biosciences, Inc. (the
“Company”) issued a press release announcing its preliminary unaudited financial results for the three months
and full-year ended December 31, 2022. A copy of this release is furnished as Exhibit 99.1 hereto.
The information
under Item 2.02 of this Current Report on Form 8-K, including the press release furnished as Exhibit 99.1, is being furnished, shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings, whether
made before or after the date hereof, regardless of any general incorporation language in any such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: January 12, 2023 |
Akoya Biosciences, Inc. |
|
|
|
|
By: |
/s/ Brian McKelligon |
|
|
Brian McKelligon |
|
|
Chief Executive Officer |
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2023 to Mar 2024